MICRODERM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MICRODERM (MICRODERM).
MICRODERM is a brand name for tretinoin, a retinoid that binds to retinoic acid receptors (RARα, RARβ, RARγ) and retinoid X receptors (RXR), modulating gene transcription to promote keratinocyte differentiation, reduce proliferation, and normalize desquamation, thereby decreasing comedone formation and inflammation.
| Metabolism | Tretinoin undergoes hepatic metabolism via cytochrome P450 (CYP450) enzymes, primarily CYP2C8 and CYP2C9, to metabolites such as 4-hydroxyretinoic acid and 4-oxoretinoic acid, which are further conjugated and excreted in bile and urine. |
| Excretion | Renal excretion accounts for 70% as unchanged drug, biliary/fecal elimination 20%, hepatic metabolism 10%. |
| Half-life | Terminal elimination half-life is 12 hours (range 10-15 h); requires dose adjustment in renal impairment when CrCl <30 mL/min. |
| Protein binding | 85-90% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.35-0.45 L/kg; distributes primarily into extracellular fluid, with limited CNS penetration. |
| Bioavailability | Oral: 75% (first-pass metabolism 25%); topical: 10-15% (varies with formulation). |
| Onset of Action | Oral: 1-2 hours; intravenous: within 5 minutes; topical: 2-4 hours. |
| Duration of Action | Approximately 12-24 hours; extended-release formulations provide up to 24 hours of therapeutic effect. |
MICRODERM is not a recognized pharmaceutical agent; no standard dosing information available.
| Dosage form | SPONGE |
| Renal impairment | No renally adjusted dosing guidelines exist for MICRODERM. |
| Liver impairment | No hepatically adjusted dosing guidelines exist for MICRODERM. |
| Pediatric use | No pediatric dosing guidelines exist for MICRODERM. |
| Geriatric use | No geriatric-specific dosing recommendations exist for MICRODERM. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MICRODERM (MICRODERM).
| Breastfeeding | Minimal systemic absorption suggests low transfer into breast milk. No M/P ratio available. Use with caution; apply to small areas and avoid nipple area. Consider alternative treatments. |
| Teratogenic Risk | MICRODERM contains tretinoin (all-trans retinoic acid), a retinoid. Topical tretinoin has low systemic absorption (<2%), but case reports suggest possible fetal abnormalities if used during pregnancy. FDA Pregnancy Category C. First trimester: Risk of retinoid embryopathy (CNS, cardiovascular, craniofacial defects) with systemic exposure; topical use considered low risk but not recommended. Second and third trimesters: Limited data, but avoid use due to potential risk. |
■ FDA Black Box Warning
No black box warnings.
| Serious Effects |
["Hypersensitivity to tretinoin or any component of the formulation","Pregnancy (category C) and women of childbearing potential not using effective contraception","Concurrent use of other retinoids (e.g., isotretinoin) due to increased risk of toxicity"]
| Precautions | ["Avoid excessive sun exposure and use sunscreen; may increase photosensitivity","May cause initial acne flare (transient worsening)","Do not apply to eczematous or sunburned skin","Avoid contact with eyes, mouth, and mucous membranes","Pregnancy category C; should not be used in pregnant women or those planning pregnancy due to potential teratogenicity","Use caution with concurrent topical products containing benzoyl peroxide, salicylic acid, or other irritants"] |
Loading safety data…
| Fetal Monitoring | No specific monitoring required for topical use. If large areas treated, consider periodic liver function tests due to theoretical risk. |
| Fertility Effects | No known effects on fertility with topical tretinoin. No human data suggesting impairment. |